Images List Premium Download Classic

Monoclonal

Monoclonal-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Multivalent fragments of antibody 3e10 and methods of use thereof
The United States Government As Represented By The Department Of Veterans Affairs
October 12, 2017 - N°20170291961

Antigen binding molecules that bind to the epitope of 3e10, and methods of use thereof are provided. The antigen binding molecule can include, for example, two or more variant single chain variable fragments (scfv) of monoclonal antibody 3e10, wherein the variant scfv has one or more insertions, deletions, or substitutions relative to a corresponding 3e10 scfv, and wherein the molecule ...
Light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging
The John Hopkins University
October 12, 2017 - N°20170290930

The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a mycobacterium tuberculosis (m. Tuberculosis) infection in a subject, as well ...
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
Dana-farber Cancer Institute, Inc.
October 12, 2017 - N°20170290911

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from ccr4-igg1 and recognizes the same epitope. This antibody contains either an igg4 or a stabilized igg4 in order to improve binding efficiency and reduce in vivo fab arm exchange. Binding of the antibodies ...
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapeutic cd47 antibodies
Tioma Therapeutics, Inc.
October 05, 2017 - N°20170283498

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, cd47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (iri) in ...
Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
October 05, 2017 - N°20170283497

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a ror1 monoclonal antibody, conferring specific immunity against ror1 positive cells. The engineered immune cells endowed with such cars are particularly ...
Human anti-il-33 neutralizing monoclonal antibody
Mitsubishi Tanabe Pharma Corporation
October 05, 2017 - N°20170283494

An antibody has an antagonistic effect against il-33. In particular an isolated human anti-il-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-il-33 monoclonal antibodies were identified, human anti-il-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ...
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antibodies to tigit
Abmuno Therapeutics Llc
October 05, 2017 - N°20170281764

The invention provides monoclonal antibodies that specifically bind to tigit. The monoclonal antibodies have the capacity for substantial activation of t cells and natural killer cells by inhibiting binding of tigit to cd155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.
Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 28, 2017 - N°20170275378

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
September 28, 2017 - N°20170275374

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a 5t4 monoclonal antibody, conferring specific immunity against 5t4 positive cells. The engineered immune cells endowed with such cars are particularly ...
Egfrviii specific chimeric antigen receptor for cancer immunotherapy
Pfizer Inc.
September 28, 2017 - N°20170275366

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an egfrviii monoclonal antibody, conferring specific immunity against egfrviii positive cells. The tcr ko engineered immune cells endowed with such cars ...
Il-23p19 monoclonal antibodies and methods of using the same
Bristol-myers Squibb Company
September 28, 2017 - N°20170275357

The present invention relates to antagonizing the activity of il-17a, il-17f and il-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for il-17a and il-17f and a binding entity that binds il-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Method for purification of monoclonal antibodies
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
September 28, 2017 - N°20170274299

Disclosed is a method for purification of monoclonal antibodies or of a fusion protein between the fc segment of an antibody and a second polypeptide, including a) an affinity chromatography step on a resin having as a matrix a crosslinked methacrylate polymer gel, on which the protein a is grafted, b) a viral inactivation step, c) a chromatography step exchanging ...
Drug delivery of temozolomide for systemic based treatment of cancer
Cedars-sinai Medical Center
September 28, 2017 - N°20170274085

The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (tmz) by conjugating tmz in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal ...
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Protein assay method specific to tracp-5b (tartrate resistant acid phosphatase 5b)
Nitto Boseki Co., Ltd.
September 21, 2017 - N°20170267782

The purpose of the present invention is to provide a monoclonal antibody that is useful in specifically assaying tartrate resistant acid phosphatase 5b (tracp-5b). A hybridoma producing a monoclonal antibody against tracp-5b, said monoclonal antibody showing higher reactivity with tracp-5b than with tartrate resistant acid phosphatase 5a (tracp-5a) and, therefore, being specific to tracp-5b, is ...
Agonistic antibody to cd27
Aduro Biotech Holdings, Europe B.v.
September 21, 2017 - N°20170267771

The invention relates to a binding compound, which binds the same epitope of human cd27 as monoclonal antibody hcd27. 15, produced by hybridoma hcd27. 15 which was deposited with the atcc in on jun. 2, 2010 under number pta-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at ...
Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
Pierre Fabre Medicament
September 21, 2017 - N°20170267766

The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to igf-1r, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to igf-1r and, by inducing internalization of igf-1r, being ...
Agents, uses and methods for treatment
H. Lundbeck A/s
September 21, 2017 - N°20170267761

The present invention relates to monoclonal anti-sortilin antibodies which have been found useful in correcting a deficient level of progranulin (pgrn). In particular, these antibodies can be used in the treatment of frontotemporal dementia (ftd) and amyotrophic lateral sclerosis (als).
Combination therapy for co-administration of monoclonal antibodies
H. Lundbeck A/s
September 21, 2017 - N°20170267753

Disclosed are methods for enhancing the efficacy of monoclonal antibody therapy, which entails co-administering a therapeutic monoclonal antibody, or a functional fragment thereof, and an effective amount of colchicine or hydroxychloroquine, or a combination thereof, to a patient in need thereof. Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the circulation of a ...
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and ...
Celldex Therapeutics, Inc.
September 21, 2017 - N°20170267750

The invention described herein is related to antibodies directed to the antigen tim-1 and uses of such antibodies for the treatment of cancer (e. G., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen tim-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences ...
Endotrophin neutralization and use thereof
Board Of Regents Of The University Of Texas System
September 21, 2017 - N°20170267749

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the c5 ...
Neutralizing antibodies to hiv-1 and their use
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
September 21, 2017 - N°20170267748

Monoclonal neutralizing antibodies that specifically bind to hiv-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting hiv using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an hiv ...
Loading